Syncona Shs GBP (GB:SYNC)
LSE:SYNC
Want to see GB:SYNC full AI Analyst Report?
Top Page
Syncona Shs GBP
(LSE:SYNC)
Select Model
Select Model
Rating:60Neutral
Price Target:
105.00 p
▲(11.82% Upside)
Action:Reiterated
Date:06/19/26
The score is anchored by balance-sheet strength (debt-free, large equity base), but is held back by inconsistent profitability and a recent drop of free cash flow to zero. Technicals are supportive with the price above major moving averages and positive MACD, while valuation remains constrained by losses implied by the negative P/E.
Positive Factors
Balance sheet strength
Zero reported total debt and a large equity base materially lower financial risk and provide durable capital to support long clinical timelines and follow-on funding. This conservative position preserves optionality and resilience during multi-year biotech development cycles.
Negative Factors
Inconsistent profitability
Shifting to consecutive loss years weakens the firm's ability to demonstrate repeatable return generation on its invested capital. Persistent negative earnings reduce retained earnings growth and constrain the pace at which the company can internally fund new investments long-term.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Zero reported total debt and a large equity base materially lower financial risk and provide durable capital to support long clinical timelines and follow-on funding. This conservative position preserves optionality and resilience during multi-year biotech development cycles.
Read all positive factors
Syncona Shs GBP (SYNC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£585.08M
Dividend YieldN/A
Average Volume (3M)483.92K
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue Growth-40.88%
EPS Growth93.65%
CountryUK
Employees1,050
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)-0.15
Shares Outstanding608,193,050
10 Day Avg. Volume510,558
30 Day Avg. Volume483,919
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)0.52
Price to Sales (P/S)9.39
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£49.14M
Syncona Shs GBP Business Overview & Revenue Model
Company Description
Syncona Limited operates as an investment fund, strategically deploying capital across a broad spectrum of investment vehicles, including hedge funds, equity funds, and long-duration alternative investments, spanning numerous asset classes. The fi...
How the Company Makes Money
Syncona makes money primarily through investment returns rather than operating revenue from selling products or services. Its core economic model is to raise and manage capital, deploy it into a concentrated portfolio of life science and biotechno...
Syncona Shs GBP Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
53
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 64.35M | 57.34M | -68.31M | 30.75M | -39.79M | 18.69M |
| Gross Profit | 64.35M | 43.36M | -68.31M | 14.10M | -51.91M | 3.68M |
| EBITDA | -74.69M | -8.80M | -143.16M | 8.14M | 0.00 | 11.15M |
| Net Income | -93.58M | -8.80M | -143.16M | 3.79M | -56.02M | 8.84M |
Balance Sheet | ||||||
| Total Assets | 1.03B | 1.05B | 1.06B | 1.25B | 1.27B | 1.33B |
| Cash, Cash Equivalents and Short-Term Investments | 213.00K | 1.92M | 1.11M | 261.00K | 11.00K | 276.00K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 13.77M | 14.95M | 11.79M | 12.22M | 13.76M | 23.55M |
| Stockholders Equity | 1.02B | 1.04B | 1.05B | 1.24B | 1.25B | 1.31B |
Cash Flow | ||||||
| Free Cash Flow | 30.03M | 0.00 | 43.91M | 20.47M | -265.00K | 262.00K |
| Operating Cash Flow | 30.03M | 23.33M | 43.91M | 20.47M | -265.00K | 262.00K |
| Investing Cash Flow | 0.00 | -15.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | -30.38M | -6.78M | -43.06M | -20.22M | 0.00 | 0.00 |
Syncona Shs GBP Technical Analysis
Neutral
93.90
Price Trends
93.93
Positive
94.72
Positive
96.18
Positive
Market Momentum
0.56
Positive
46.84
Neutral
34.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SYNC, the sentiment is Neutral. The current price of 93.9 is below the 20-day moving average (MA) of 98.95, below the 50-day MA of 93.93, and below the 200-day MA of 96.18, indicating a neutral trend. The MACD of 0.56 indicates Positive momentum. The RSI at 46.84 is Neutral, neither overbought nor oversold. The STOCH value of 34.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:SYNC.
Syncona Shs GBP Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £1.83B | 13.98 | 4.51% | 2.40% | 68.95% | 109.67% | |
72 Outperform | £1.31B | 11.20 | 14.60% | 9.91% | -21.74% | 58.92% | |
70 Outperform | £983.73M | 9.48 | 8.51% | ― | 11.00% | ― | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
67 Neutral | £123.62M | 37.58 | 1.79% | 3.29% | -9.37% | ― | |
61 Neutral | £574.23M | 8.70 | 7.16% | ― | -35.12% | ― | |
60 Neutral | £585.08M | -66.81 | -9.02% | ― | -40.88% | 93.65% |
* Financial Sector Average
GB:SYNC
Syncona Shs GBP
96.20
3.20
3.44%
GB:ASHM
Ashmore Group PLC
197.70
58.68
42.21%
GB:GROW
Molten Ventures
587.50
299.50
103.99%
GB:IPO
IP Group plc
65.00
18.25
39.04%
GB:MERC
Mercia Asset Management
29.25
0.15
0.52%
GB:CLDN
Caledonia Investments
357.50
-5.13
-1.42%
Syncona Shs GBP Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresShareholder Meetings
Syncona Sets £250m Return Target as Portfolio Advances to Late-Stage Trials
Positive
Jun 18, 2026
Syncona reported largely stable full-year results, with net assets of £1.04 billion and modest gains in its life sciences portfolio driven by a valuation uplift at Beacon Therapeutics following an oversubscribed Series C financing. The group ...
Business Operations and StrategyExecutive/Board Changes
Syncona appoints veteran investment specialist Norman Crighton to board
Positive
Jun 17, 2026
Syncona Ltd has appointed veteran investment company specialist Norman Crighton as an independent non-executive director from 1 July 2026, adding more than three decades of experience in investment banking, fund management and board governance to ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.